118 related articles for article (PubMed ID: 3945437)
1. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.
Piver MS; Lele SB; Patsner B; Emrich LJ
Obstet Gynecol; 1986 Feb; 67(2):261-4. PubMed ID: 3945437
[TBL] [Abstract][Full Text] [Related]
2. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report.
Piver MS; Lele S; Barlow JJ
Obstet Gynecol; 1980 Sep; 56(3):370-2. PubMed ID: 7422177
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma.
Cornelison TL; Baker TR; Piver MS; Driscoll DL
Gynecol Oncol; 1995 Nov; 59(2):243-8. PubMed ID: 7590480
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
Ayoub J; Audet-Lapointe P; Méthot Y; Hanley J; Beaulieu R; Chemaly R; Cormier A; Déry JP; Drouin P; Gauthier P
Gynecol Oncol; 1988 Oct; 31(2):327-37. PubMed ID: 2971597
[TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
Kline RC; Freedman RS; Jones LA; Atkinson EN
Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831
[No Abstract] [Full Text] [Related]
6. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Whitney CW; Brunetto VL; Zaino RJ; Lentz SS; Sorosky J; Armstrong DK; Lee RB;
Gynecol Oncol; 2004 Jan; 92(1):4-9. PubMed ID: 14751130
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.
Bafaloukos D; Aravantinos G; Samonis G; Katsifis G; Bakoyiannis C; Skarlos D; Kosmidis P
Oncology; 1999 Apr; 56(3):198-201. PubMed ID: 10202274
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay.
Stratton JA; Mannel RS; Rettenmaier MA; Berman ML; DiSaia PJ
Gynecol Oncol; 1989 Jan; 32(1):55-9. PubMed ID: 2535831
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia.
Carlson JA; Allegra JC; Day TG; Wittliff JL
Am J Obstet Gynecol; 1984 May; 149(2):149-53. PubMed ID: 6232850
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
13. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
Hardy JR; Powles TJ; Judson IR; Sinnett HD; Ashley SE; Coombes RC; Ellin CL
Eur J Cancer; 1990; 26(7):824-7. PubMed ID: 2145904
[TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate.
Hoffman MS; Roberts WS; Cavanagh D; Praphat H; Solomon P; Lyman GH
Gynecol Oncol; 1989 Oct; 35(1):75-7. PubMed ID: 2477317
[TBL] [Abstract][Full Text] [Related]
15. [Results of hormone and chemotherapy of patients with cancer of the corpus uteri].
Ploch E
Nowotwory; 1985; 35(3):255-61. PubMed ID: 4088901
[No Abstract] [Full Text] [Related]
16. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
[TBL] [Abstract][Full Text] [Related]
17. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
Mauriac L; Durand M; Bonichon F; Chauvergne J
Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study.
Pierga JY; Dieras V; Paraiso D; Dorval T; Palangie T; Beuzeboc P; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
Gynecol Oncol; 1996 Jan; 60(1):59-63. PubMed ID: 8557229
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study.
Cohen CJ; Deppe G; Bruckner HW
Obstet Gynecol; 1977 Oct; 50(4):415-7. PubMed ID: 904803
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
